| Literature DB >> 33961055 |
Katherine E Burgomaster1, Bryant M Foreman1, Maya A Aleshnick1, Bridget C Larman1, David N Gordon1, Sonia Maciejewski1, Kaitlyn M Morabito2, Julie E Ledgerwood2, Martin R Gaudinski2, Grace L Chen2, John R Mascola2, Kari Debbink1,3, Kimberly A Dowd1, Barney S Graham2, Theodore C Pierson1.
Abstract
Zika virus (ZIKV) deoxyribonucleic acid vaccine VRC5283 encoding viral structural genes has been shown to be immunogenic in humans. Recognizing that antigenically related flaviviruses cocirculate in regions with ZIKV activity, we explored the degree of antibody cross-reactivity elicited by this vaccine candidate using genetically diverse flaviviruses. The antibody response of vaccinated individuals with no evidence of prior flavivirus infection or vaccine experience had a limited capacity to bind heterologous viruses. In contrast, vaccine-elicited antibodies from individuals with prior flavivirus experience had a greater capacity to bind, but not neutralize, distantly related flaviviruses. These findings suggest that prior flavivirus exposure shapes the humoral immune response to vaccination. Published by Oxford University Press for the Infectious Diseases Society of America 2021.Entities:
Keywords: DNA vaccine; Zika virus; cross-reactive antibodies; neutralization
Mesh：
Substances：
Year: 2021 PMID： 33961055 PMCID： PMC8599923 DOI： 10.1093/infdis/jiab185
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226